Finepoint Capital LP
- SEC CIK
- 0001608126
- Latest filing
- Aug 13, 2026
Holdings in Q4 2023
Holdings as of Dec 31, 2023, filed Feb 13, 2024. Long positions only; changes compare share counts with Q3 2023.
- Positions
- 26
- −4 vs. Q3 2023
- Portfolio value
- $289.1M
- +$88.3M (+44.0%) vs. Q3 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CYTKCytokinetics Inc | COM NEW | 431,693 | $36.0M | 12.5% | 00.0% | Unchanged | History |
| ACADAcadia Pharmaceuticals Inc | COM | 769,653 | $24.1M | 8.3% | +213,100+38.3% | Added | History |
| FOLDAmicus Therapeutics, Inc. | COM | 1,489,025 | $21.1M | 7.3% | 00.0% | Unchanged | History |
| ARVNArvinas, Inc. | COM | 504,700 | $20.8M | 7.2% | 00.0% | Unchanged | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 163,772 | $20.6M | 7.1% | 00.0% | Unchanged | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 556,928 | $20.3M | 7.0% | 00.0% | Unchanged | History |
| Home Plate Acquisition Corp43734R111 | *W EXP 09/30/202 | 331,416 | $20.0M | 6.9% | −358,584−52.0% | Reduced | – |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 458,659 | $18.6M | 6.4% | 00.0% | Unchanged | History |
| RVMDRevolution Medicines, Inc. | COM | 617,100 | $17.7M | 6.1% | +190,100+44.5% | Added | History |
| LBRDKLiberty Broadband Corp | COM SER C | 184,460 | $14.9M | 5.1% | +184,460 | New | History |
| RLAYRelay Therapeutics, Inc. | COM | 1,317,870 | $14.5M | 5.0% | +447,000+51.3% | Added | History |
| MORFMorphic Holding, Inc. | COM | 496,856 | $14.3M | 5.0% | +171,500+52.7% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 145,357 | $14.0M | 4.8% | 00.0% | Unchanged | History |
| TVTXTravere Therapeutics, Inc. | COM | 1,435,321 | $12.9M | 4.5% | +539,500+60.2% | Added | History |
| PRTAProthena Corp Public Ltd Co | SHS | 349,300 | $12.7M | 4.4% | 00.0% | Unchanged | History |
| SLDBSolid Biosciences Inc. | COM NEW | 961,251 | $5.90M | 2.0% | 00.0% | Unchanged | History |
| CLDICalidi Biotherapeutics, Inc. | CL A | 125,000 | $188.8K | 0.1% | 00.0% | Unchanged | History |
| Churchill Capital Corp VII17144M110 | *W EXP 02/29/202 | 548,000 | $71.3K | <0.1% | 00.0% | Unchanged | – |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 895,000 | $62.7K | <0.1% | +563,584+170.1% | Added | History |
| CNDAWConcord Acquisition Corp II | *W EXP 99/99/999 | 408,333 | $53.1K | <0.1% | 00.0% | Unchanged | History |
| CLDWWCalidi Biotherapeutics, Inc. | *W EXP 03/14/202 | 655,200 | $32.8K | <0.1% | 00.0% | Unchanged | History |
| Ross Acquisition Corp IIG7641C114 | *W EXP 02/01/202 | 439,666 | $24.6K | <0.1% | 00.0% | Unchanged | – |
| Compass Digital Acquisitn CoG2476C123 | *W EXP 09/29/202 | 459,906 | $22.3K | <0.1% | 00.0% | Unchanged | – |
| Marblegate Acquisition Corp.56608A113 | *W EXP 08/31/202 | 735,000 | $22.1K | <0.1% | 00.0% | Unchanged | – |
| Swiftmerge Acquisition CorpG63836111 | *W EXP 12/13/202 | 490,000 | $20.1K | <0.1% | 00.0% | Unchanged | – |
| Ys Biopharma Co LtdG9845F117 | *W EXP 03/15/202 | 489,999 | $13.3K | <0.1% | 00.0% | Unchanged | – |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| FLYYSpirit Aviation Holdings, Inc. | COM | – | $27.9M |
Sold out since Q3 2023 (5)
Positions held at the end of Q3 2023 that are gone from this filing.
| Security | Class | Shares in Q3 2023 | Value in Q3 2023 | % of portfolio in Q3 2023 | History |
|---|---|---|---|---|---|
| CERECerevel Therapeutics Holdings, Inc. | COM | 563,345 | $12.3M | 6.1% | History |
| Ares Acquisition CorporationG33032122 | *W EXP 99/99/999 | 504,706 | $333.6K | 0.2% | – |
| Bridgetown Holdings LtdG1355U121 | *W EXP 09/30/202 | 895,000 | $304.3K | 0.2% | – |
| Churchill Capital Corp VI17143W119 | *W EXP 02/17/202 | 540,000 | $86.4K | <0.1% | – |
| Churchill Capital Corp V17144T115 | *W EXP 10/29/202 | 612,000 | $0 | 0.0% | – |